Proactive Investors
13 Oct 2026, 07:39 UTC · 1h ago
Reach holds profit outlook as Google referral disruption hits sales
Impact · against what's priced in
Reach faces significant downward pressure as systemic revenue erosion across digital and print is only partially offset by aggressive cost-cutting. Arecor Therapeutics provides a positive update on its insulin and GLP-1 pipeline, though the impact is smaller relative to Reach's fundamental shifts.
- RCH−0.50
No priced-in read yet
- In context
Total revenue fell 14.1% year-on-year, driven by a 20.3% drop in digital revenue due to Google referral disruptions and a 12% decline in print revenue. While the £95.1 million profit target is maintained, it relies on operational cost savings exceeding 10% to offset £35-£40 million in restructuring costs.
Read from the article alone
Search tags
